相关实验视频

Updated: Feb 26, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

860

风险评估得分作为肺动脉高血压试验中代用终点的研究

Yongqi Liu1, R James White2, Sang Wan Lee1

  • 1Department of Statistics, The Ohio State University, Columbus, OH, USA.

American journal of respiratory and critical care medicine
|February 25, 2026
PubMed
概括

在肺动脉高血压试验中,REVEAL Lite 2 (RL2) 和欧洲四层 (E4) 等综合风险评分显示出比6分钟步行距离 (6MWD) 更强大的代用终点. 这些分数更好地介导治疗效果,特别是在高风险患者中.

关键词:
6MWD 6MWD 6MWD 6MWD 6MWD 6MWD 6MWD 6MWDE3 E3 的意思是什么?E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E4 E6 E7 E7 E7 E7 E7 E7 E8 E8 E8 E8 E8 E8 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E9 E7 E9 E9 E9 E9 E7 E9 E9 E7 E9 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7FPHN FPHN 在线观看肺动脉高血压是肺动脉高血压.RL2 RL2 在线阅读调解分析 调解分析替代终点 替代终点

更多相关视频

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.8K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.9K

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
502
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
52
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
656